జర్నల్ ఆఫ్ కార్సినోజెనిసిస్ & మ్యూటాజెనిసిస్

నైరూప్య

Different Effects of the RNASEL R462Q Mutation on the Risk of Developing Prostate and Cervical Cancer in Latin American Subjects: A Meta-Analysis

Porchia ML, Meda E, Zepeda RC, Orduña-Salazar AA, Juárez-Salazar G, González-Mejia ME and Aguirre G

Background: Prostate and cervical tissues are highly susceptible to carcinogenesis. Furthermore, some reports suggest that alterations in RNASEL have been associated with augmented risk of developing cancer, specifically the arginine to glutamine mutation at position 462 (R462Q). However, with conflicting results of the R462Q mutation on cancer risk, our goal was to determine what effect this mutation had on prostate and cervical cancers in Latin Americans.

Methods: PubMed, EBSCO, SCOUPS, Wiley and OVID databases, and study bibliographies were systematically searched for case-control studies that examined for the R462Q mutation until June 2015. Odds ratios (ORs) and 95%CI were calculated from the genotype data. The pooled ORs were obtained by the Peto method for the heterozygous, the homozygous, the dominant, the recessive, and the allelic genetic models. Heterogeneity was assessed by the Q-test and I2-test. Publication bias was assessed by the Begg and Mazumdar’s test and the Egger’s test. The sensitivity was determined by reevaluation of the pooled OR after removal of one study.

Results: From the 153 retrieved studies, four studies met the inclusion criteria (n=808 subjects). The pooled results did not indicate any association between R462Q and overall cancer risk for any of the genetic model assessed. However, when stratified by type of cancer, the homozygous and the recessive genetic models demonstrated a significant association between prostate cancer (OR=2.26, 95%CI=1.15-4.44, p<0.05 and OR=2.18, 95%CI=1.12-4.23, p<0.05, respectively) and cervical cancer (OR=0.32, 95%CI=0.13-0.74, p<0.01 and OR=0.35, 95%CI=0.16-0.77, p<0.01, respectively). Furthermore, the risk associated with this mutation for prostate cancer and cervical cancer was different (p<0.01).

Conclusion: Here we denote, for Latin Americans, the different effects the RNASEL R462Q mutation has for prostate (increased risk) and cervical (decreased risk) cancers.